Clinical Trial

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.

Study acronym: PRISMA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET/CT imaging in mTNBC lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-26.
Trial Details
NCT Number NCT06059469
Lead Sponsor Jules Bordet Institute
Conditions TNBC - Triple-Negative Breast Cancer
Enrollment 20 participants
Start Date 2022-05-30
Primary Completion 2025-06-02 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-18